Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Therapeutic Solutions International (OTCMKTS:TSOI) Stock Extends Rally: Jumps 70% In a Week

Therapeutic Solutions International (OTCMKTS:TSOI) was up 20% and 70% in a week after announcing positive findings from a pilot clinical study in 20 participants.

Market Stats

On Monday, TSOI stock ended higher by 20% to $0.0348 with more than 21.52 million shares, compared to its average volume of 7.97 million shares. The stock has moved within a range of $0.0275 – 0.0369 after opening trading at $0.0293.

Reports Positive Clinical Data on QuadraMune® Reduction of SARS-CoV-2 Spike Protein Induced Inflammation

Ten patients were given a placebo for seven days, and ten were given twice daily doses of QuadraMune. Three-time points were used to collect blood monocytes and treat them in vitro with SARS-CoV-2 spike protein. At all three time points, the inflammatory cytokine interleukin-6 production was shown to be considerably lower.

The company’s board member and co-QuadraMune inventor, Dr. Thomas Ichim, stated that QuadraMune is an exceptional nutraceutical supplement capable of suppressing inflammatory pathways related to COVID-19 death while also inhibiting immune-suppressive enzymes like indolamine two, three dioxygenases. Ichim explained that with new variants of concern emerging, there is a need to continue looking at a variety of immune-modulatory approaches that can possibly synergize with present vaccination efforts.

In addition, last week the company was given a notice of allowance for a patent on QuadraMune’s covid-19 inhibiting and immune-modulatory properties. Therefore, TSOI is worth keeping an eye on.

Key Quote

“QuadraMune is a unique nutraceutical supplement that suppresses inflammatory pathways associated with COVID-19 mortality, while at the same time inhibits immune suppressive enzymes such as indolamine 2,3 dioxygenase,” said Dr. Thomas Ichim, co-inventor of QuadraMune and Board Member of the Company. “As new variants of concern keep emerging, we believe it is necessary to continue exploring various immune modulatory strategies that potentially synergize with existing vaccination efforts.”

Traders Corner

TSOI stock is trading above the 20-Day and 50-Day Moving averages of $0.0289 and $0.0329 respectively. The stock is trading in neutral zone with the RSI at 55.  The stock is up 35% in the past month.  

Published by Jon Williams

Jon graduated from the University of Michigan with a degree in finance. He is an avid investor and enjoys reporting on the markets. When he is not in front of a computer he enjoys playing golf and watching basketball.